Aggressive Lymphomas
News
Factors linked to B-NHL in Palestinians, Israelis
New research has revealed factors that may increase the risk of B-cell non-Hodgkin lymphoma (B-NHL) in Israelis and Palestinians. This large-scale...
News
European Commission approves rituximab biosimilar
The European Commission has approved a biosimilar rituximab product, Truxima™, for all the same indications as the reference product, MabThera....
News
Immunotherapy receives fast track designation
The US Food and Drug Administration (FDA) has granted fast track designation to CMD-003 (baltaleucel-T) for patients with relapsed/refractory...
News
Styrene exposure linked to myeloid leukemia, HL
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that,...
News
G-CSF could prevent infertility in cancer patients
Granulocyte colony-stimulating factor (G-CSF) could prevent infertility in male cancer patients, according to preclinical research published in...
News
How EBV causes lymphoma, other cancers
among uninfected cells (blue) Image courtesy of Benjamin Chaigne-Delalande New research published in Nature Communications appears to explain how...
News
Team creates online database of cancer mutations
Researchers have developed an online “knowledgebase” called CIViC, an open access resource for collecting and interpreting information from...
News
Investigators report new risk loci for CLL
Investigators say they have identified 9 new risk loci for chronic lymphocytic leukemia (CLL). The team says the research, published in Nature...
News
Obinutuzumab approved to treat FL in Canada
Health Canada has approved the use of obinutuzumab (Gazyva®), an anti-CD20 monoclonal antibody, in patients with follicular lymphoma (FL).
Conference Coverage
Neuropathic pain puts cancer survivors out of work
Chronic neuropathic pain is a barrier to employment for many cancer survivors.
From the Journals
Long view shows doubling of survival in non-Hodgkin lymphoma
The 5-year relative survival rate for non-Hodgkin lymphoma in the United States went from 33% in 1950-1954 to 71.2% in 2008-2013.